RE: cytokine storm patent5 Oct 2022 10:36
Chief executive Jeremy Skillington said: “Enhanced IP protection of our assets across key markets, such as the US, increases the overall value of these products to potential partners.
“This is particularly important as we move closer to the completion of our POLB 001 LPS human challenge trial, with initial results expected by year-end 2022."